Status: Recruiting
Rifaximin SSD in Dementia Trial
Using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.
Participants needed: 20
Trial details
Phase: Phase 1, Phase 2Age: 65+Biological sex: AllType: InterventionalSponsor: Jasmohan BajajUpdated: Apr 3, 2026Locations: 1
Eligibility criteria
Probable Alzheimer's Disease (AD) or Vascular Dementia (VaD) mild or moderate ba... [+5]
Dementia not due to AD or VaD [+12]